PMID: 7545422Aug 1, 1995Paper

The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro

British Journal of Haematology
M A SmithJ G Smith

Abstract

This study examines the effect of pretreatment in liquid culture of acute myeloid leukaemic (AML) progenitors with recombinant human IL-3 or G and GM-CSF. Prior to and following cytokine priming, the sensitivity of cells to cytosine arabinoside (Ara-C) at concentrations ranging from 10(-12) to 10(-4) M was assessed in clonogenic culture. In addition, the initial percentage of AML cells in S phase was assessed and their subsequent kinetic response to cytokine treatment evaluated by FACScan analysis. Light-density marrow cells (LDMCs) from 19 AML patients were initially T-cell and monocyte depleted in order to remove potential sources of endogenous cytokine production prior to in vitro investigation. LDMCs were incubated in liquid phase for 7 d in a chemically defined complete medium with or without cytokines. Clonogenic data from fresh AML LDMCs not pretreated with growth factors demonstrated a heterogenous response to Ara-C. In only 4/15 marrows tested clonogenically was there any improvement in sensitivity to Ara-C following cytokine priming. S-phase data on all 19 marrows were similarly variable either before or after cytokine preincubation. There was no discernible correlation between clonogenic and kinetic data, nor could a...Continue Reading

References

Jun 1, 1992·Leukemia Research·E MontserratC Rozman
Oct 1, 1990·Biochemical Society Transactions·T J van BerkelM K Bijsterbosch
Nov 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A RojasH Johns
Jan 1, 1989·Leukemia Research·M S LinetM Szklo
Aug 1, 1986·Journal of Medical Genetics·J M ConnorC D Forbes
Jul 1, 1985·British Journal of Haematology·J G SmithR M Rowan
May 1, 1974·British Journal of Haematology·M H TattersallA V Hoffbrand
Dec 29, 1971·Nature: New Biology·G V Rama ReddyS S Hendler

❮ Previous
Next ❯

Citations

Jan 1, 1997·Stem Cells·M EderA Ganser
Sep 29, 2000·Pharmacology & Therapeutics·G J PetersS P Ackland
Dec 19, 2013·Computational Intelligence and Neuroscience·Zhe Chen
Jun 8, 2012·International Journal of Evolutionary Biology·Paul C KirchbergerStephan Koblmüller
Feb 19, 2002·Expert Opinion on Biological Therapy·Øystein BruserudStein Ove Døskeland
Dec 30, 2014·Molecular Aspects of Medicine·Alessandra di MasiClara Nervi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.